Highlight
The SINGLE-CLOSURE trial is the first randomized study comparing single vs double ProGlide vascular closure devices after transfemoral aortic valve replacement (TAVR). The trial found the single-ProGlide approach to be noninferior regarding access-site vascular complications, with a similar safety profile and no increase in major adverse events. This simplified closure strategy may reduce procedural complexity and potentially mitigate risks related to vascular stenosis associated with multiple device deployment.
Study Background
Specialty calculators
For clinical reference; use professional judgment.
